J&J Sees International OTC Presence, Pfizer Pickups As Growth Engines
This article was originally published in The Pink Sheet Daily
Executive Summary
Firm expects to launch OTC Zyrtec without exclusivity at year-end, and looks to the antihistamine product as well as Nicorette and new products using rapid release technology expected as growth drivers.
You may also be interested in...
Judge Orders FDA, Food Safety Group To Set FSMA Implementation Date
FDA’s delays in implementing the Food Safety Modernization Act violated FSMA and the Administrative Procedures Act, a federal court finds in an April 22 order. The agency must meet with plaintiff Center for Food Safety to agree on new implementation deadlines by May 20.
Judge Orders FDA, Food Safety Group To Set FSMA Implementation Date
FDA’s delays in implementing the Food Safety Modernization Act violated FSMA and the Administrative Procedures Act, a federal court finds in an April 22 order. The agency must meet with plaintiff Center for Food Safety to agree on new implementation deadlines by May 20.
Whey Recall Grows, But Plainview Approach May Prevent A Peanut Replay
The recall of whey protein ingredients rippling its way through the dietary supplement industry shows that companies must take a risk-based approach to product safety and cannot rely on good manufacturing practices alone to protect them